大行评级｜美银：首予康方生物“买入”评级及目标价162.8港元

Core Viewpoint - Bank of America Securities initiates coverage of Kangfang Biopharma with a "Buy" rating and a target price of HKD 162.8, citing strong clinical trial data for the key drug ivonescimab in China as a solid reference for global trial results [1] Group 1 - The company is expected to reveal multiple global and China Phase III clinical trial data this year [1] - The inclusion in the national medical insurance directory, expansion of indications, and new drug approvals are accelerating the commercialization process in China, with expectations of reaching breakeven this year [1] - The company's rich R&D pipeline provides long-term growth momentum and new licensing opportunities [1]